Kimi Iguchi - 21 Feb 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
CFO & Treasurer
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Kimi Iguchi
Issuer symbol
SAGE
Transactions as of
21 Feb 2023
Net transactions value
+$1,360
Form type
4
Filing time
23 Feb 2023, 17:03:01 UTC
Previous filing
15 Feb 2023
Next filing
17 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Options Exercise $1,020 +750 +1.2% $1.36 62,310 21 Feb 2023 Direct
transaction SAGE Common Stock Options Exercise $340 +250 +0.4% $1.36 62,560 23 Feb 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Options Exercise $0 -750 -13% $0.000000 4,892 21 Feb 2023 Common Stock 750 $1.36 Direct F1
transaction SAGE Stock Option (Right to Buy) Options Exercise $0 -250 -5.1% $0.000000 4,642 23 Feb 2023 Common Stock 250 $1.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on July 23, 2016.